Advisors
Goldman, Sachs & Co. is acting as financial advisor to
Beckman Coulter in connection with the transaction. Latham &
Watkins, LLP is serving as legal counsel to Beckman Coulter in
connection with the transaction.
Investor Webcast Event
Danaher will host a conference call to discuss the transactions
on February 7, 2024 at 8:30 AM ET. The U.S. dial-in number is
800-967-7134; the international dial-in number is 719-325-2490;
with reference ID Code 3770892. A telephone replay will be
available by dialing 888-203-1112 in the US; and 719-457-0820
internationally; with ID Code 3770892. The replay will be available
through February 14, 2024. The
conference call and replay will also be available via webcast in
the Investor section of www.danaher.com.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange
County, California, develops, manufactures and markets
products that simplify, automate and innovate complex
biomedical tests. More than 200,000 Beckman Coulter systems operate
in laboratories around the world, supplying critical information
for improving patient health and reducing the cost of care.
Recurring revenue, consisting of consumable supplies (including
reagent test kits), service and operating-type lease payments,
represent about 80% of the company's 2009 revenue of $3.3 billion. For more information, visit
www.beckmancoulter.com.
Additional Information and Where to Find It
The tender offer proposed by Danaher Corporation ("Danaher")
referred to in this release has not yet commenced, and this release
is neither an offer to purchase nor a solicitation of an offer to
sell securities. If and when the tender offer is commenced, (i)
Danaher will file with the Securities and Exchange Commission (the
"SEC") a tender offer statement and (ii) Beckman Coulter, Inc. (the
"Company") will file with the SEC a Solicitation/Recommendation
Statement on Schedule 14D-9. INVESTORS AND STOCKHOLDERS ARE URGED
TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE,
LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE
SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CAREFULLY
WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Investors may obtain a free copy of these documents
(if and when it becomes available) and other relevant documents
filed with the SEC through the web site maintained by the SEC at www.sec.gov. In addition, investors
and stockholders will be able to obtain free copies of these
materials filed by the Company by contacting Investor Relations by
telephone at (714) 961-6320, by mail at Beckman Coulter, Inc.,
Investor Relations, 250 S. Kraemer Blvd, Brea, California 92822, or by going to
the Company's Investor Relations page on its corporate web site at
www.beckmancoulter.com.
Note on Forward-Looking Statements
Certain statements either contained in or incorporated by
reference into this document are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including, but
not limited to, statements regarding the combined companies' plans
following, and the expected completion of, the proposed
acquisition. These forward-looking statements involve certain risks
and uncertainties that could cause actual results to differ
materially from those indicated in such forward-looking statements
and generally include statements that are predictive in nature and
depend upon or refer to future events or conditions. Risks and
uncertainties include the ability of the Company and Danaher to
complete the transactions contemplated by the Merger Agreement,
including the parties' abilities to satisfy the conditions to the
consummation of the proposed acquisition; the possibility of any
termination of the Merger Agreement; the timing of the tender offer
and the subsequent merger; uncertainties as to how many of the
Company's stockholders will tender their shares of common stock in
the tender offer; the possibility that various other conditions to
the consummation of the tender offer or the subsequent merger may
not be satisfied or waived, including that a governmental entity
may prohibit, delay or refuse to grant approval for the
consummation of the acquisition; other uncertainties pertaining to
the business of the Company or Danaher; product safety; legislative
and regulatory activity and oversight; the continuing global
economic uncertainty and other risks detailed in (i) the Company's
public filings with the SEC from time to time, including the
Company's most recent Annual Report on Form 10-K for the year ended
December31, 2009, Quarterly Reports on Form 10-Q and its
subsequently filed SEC reports, each as filed with the SEC, and
(ii) Danaher's public filings with the SEC from time to time,
including Danaher's most recent Annual Report on Form 10-K for the
year ended December 31, 2023,
Quarterly Reports on Form 10-Q and its subsequently filed SEC
reports, each as filed with the SEC, in each case, which contains
and identifies important factors that could cause actual results to
differ materially from those contained in the forward-looking
statements. The reader is cautioned not to unduly rely on these
forward-looking statements. Each of the Company and Danaher
expressly disclaims any intent or obligation to update or revise
publicly these forward-looking statements except as required by
law.
|
Contacts:
|
Beckman
Coulter
|
|
SOURCE